Total submissions: 7
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Natera, |
RCV000410263 | SCV007525899 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2025-07-18 | criteria provided, single submitter | clinical testing | The c.13132C>T variant in SACS is a nonsense variant predicted to introduce a stop codon at amino acid 4378. This variant is expected to result in nonsense mediated decay, truncation, or a dysfunctional protein product. This variant is rare in the general population with a frequency below the threshold expected for the associated phenotype(s). This variant has been observed in one or more individuals affected with the associated recessive disease, as either homozygous or compound heterozygous with a second variant (PMID: 20852969, 31429931, 30638817). Additionally, this variant has been observed to segregate in affected family members (PMID: 30638817). Given the available evidence, this variant is classified as Pathogenic. |
| Laboratorio de Genetica e Diagnostico Molecular, |
RCV000410263 | SCV006309619 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2023-09-13 | criteria provided, single submitter | clinical testing | ACMG classification criteria: PVS1 strong, PM2 moderate, PM3 strong, PP1 moderate |
| Fulgent Genetics, |
RCV000410263 | SCV005632149 | pathogenic | Charlevoix-Saguenay spastic ataxia | 2024-01-30 | criteria provided, single submitter | clinical testing | |
| PROSPAX |
RCV000410263 | SCV005061928 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-01-01 | criteria provided, single submitter | research | |
| 3billion | RCV000410263 | SCV002521153 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2022-05-22 | criteria provided, single submitter | clinical testing | The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: <0.001%). Stop-gained (nonsense): predicted to result in a loss or disruption of normal protein function through protein truncation. The predicted truncated protein may be shortened by less than 10%. The variant has been reported to be in trans with a pathogenic variant as either compound heterozygous or homozygous in at least 2 similarly affected unrelated individuals (PMID: 30638817). The variant has been reported to be associated with SACS related disorder (ClinVar ID: VCV000370756 / PMID: 20852969). Therefore, this variant is classified as likely pathogenic according to the recommendation of ACMG/AMP guideline. |
| Labcorp Genetics |
RCV001865265 | SCV002243937 | pathogenic | Spastic paraplegia | 2025-06-12 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg4378*) in the SACS gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 202 amino acid(s) of the SACS protein. This variant is present in population databases (rs747868017, gnomAD 0.0009%). This premature translational stop signal has been observed in individuals with spastic ataxia of Charlevoix-Saguenay (PMID: 20852969, 30638817). ClinVar contains an entry for this variant (Variation ID: 370756). This variant disrupts a region of the SACS protein in which other variant(s) (p.Tyr4538*) have been determined to be pathogenic (internal data). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |
| Counsyl | RCV000410263 | SCV000486150 | likely pathogenic | Charlevoix-Saguenay spastic ataxia | 2016-04-12 | no assertion criteria provided | clinical testing | This submission and the accompanying classification are no longer maintained by the submitter. For more information on current observations and classification, please contact variantquestions@myriad.com. |